| Sign In to gain access to subscriptions and/or personal tools. |
Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancyImmunology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Rheumatology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Immunology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Immunology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Rheumatology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Obstretics and Gynecology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Nephrology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Immunology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Immunology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Rheumatology Department, University General Hospital Gregorio Marañón, Madrid, Spain
Rheumatology Department, University General Hospital Gregorio Marañón, Madrid, Spain, fjlopezlongo{at}hotmail.com We report one case of pregnancy-onset severe diffuse proliferative nephritis in a patient with systemic lupus erythematosus (SLE), who was successfully treated with a combination of anti-tumour necrosis factor (TNF)-alpha, plasmapheresis and high-dose intravenous gammaglobulin. No flares were observed either in clinical symptoms or in laboratory examinations during pregnancy or after delivery. Her autoantibodies except fluorescent anti-nuclear antibodies were negative. We suggest that a combination of anti-TNF-alpha, plasmapheresis and high-dose intravenous gammaglobulin may be a safe and effective therapy for pregnant patients suffering severe lupus nephritis.
Key Words: systemic lupus erytematosus pregnancy etanercept intravenous gammaglobulin and plasmapheresis.
Lupus, Vol. 15, No. 12,
881-885 (2006) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||


